Photochemical internalisation (PCI) is a technology developed to unlock the full potential of drugs by targeted illumination of a well-defined area of the body, following the administration of our proprietary product and the active drug. Since the effect occurs only where light is applied, PCI is a localised targeted therapy.

The PCI effect is obtained by the use of a photosensitising compound that attaches to the cellular membrane of the target cells. During uptake of therapeutic drug molecules by endocytosis, the photosensitiser becomes incorporated in the membrane of the endocytic vesicles and co-localised with the drug. Following illumination with light at a wavelength that activates the photosensitiser, the integrity of the endosomal membrane is disturbed and the drug is released in the cytosol where it can reach its target of action.

PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

PCI Biotech’s lead candidate is the proprietary photosensitiser fimaporfin.